Q1 25 EPS
$-0.36
MISS 4.08%
Est. $-0.35
Q1 25 Revenue
$5.4M
MISS 19.84%
Est. $6.7M
vs S&P Since Q1 25
+2,720.0%
BEATING MARKET
TNGX +2,749.5% vs S&P +29.5%
Market Reaction
Did TNGX Beat Earnings? Q1 2025 Results
Tango Therapeutics posted a disappointing first quarter, missing on both the top and bottom lines as collaboration revenue slipped and losses widened. The clinical-stage oncology company reported Q1 2025 revenue of $5.39 million, falling 19.84% short… Read more Tango Therapeutics posted a disappointing first quarter, missing on both the top and bottom lines as collaboration revenue slipped and losses widened. The clinical-stage oncology company reported Q1 2025 revenue of $5.39 million, falling 19.84% short of the $6.73 million consensus estimate and declining 16.7% from the year-ago period, driven primarily by lower research costs incurred under its collaboration, which reduced the amount of revenue recognized. EPS came in at -$0.36, missing the -$0.35 consensus by 4.08%, as the net loss widened to $39.88 million from $37.91 million in Q1 2024. In response to market conditions, Tango is scaling back preclinical spending and target discovery efforts, a strategic shift that extends its $216.70 million cash runway into Q1 2027. Looking ahead, the company expects a pivotal TNG462 Phase 1/2 clinical data update in the second half of 2025, with a combination trial alongside Revolution Medicines' RAS(ON) inhibitors set to begin enrolling in Q2 2025.
Key Takeaways
- • Decreased collaboration revenue due to lower research costs under collaboration agreement
- • Reduced R&D expenses from discontinued clinical programs TNG908 and TNG348
- • Increased R&D spend on advancement of TNG961 and TNG456
- • Higher G&A expenses due to increased personnel-related costs
TNGX YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
TNGX Revenue by Segment
With YoY comparisons, source: SEC Filings
“Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor. We anticipate presenting a fulsome efficacy, safety and tolerability data update on TNG462 monotherapy later this year, with a focus on pancreatic and lung cancer, and remain on track with our goal of initiating our first TNG462 monotherapy registrational study in pancreatic cancer next year. We also are moving forward rapidly with key clinical combinations and, based on strong preclinical data, we are focused on combining TNG462 with Revolution Medicine's RAS(ON) inhibitors daraxonrasib and zoldonrasib in pancreatic and lung cancer. Finally, given market conditions and our strong conviction in TNG462, we have taken steps to extend our cash runway and focus resources on our PRMT5 programs, reducing spend on our preclinical pipeline and deferring some clinical combination studies designed primarily to assess tolerability with standard-of-care regimens.”
— Barbara Weber, Q1 2025 Earnings Press Release
TNGX Earnings Trends
TNGX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TNGX EPS Trend
Earnings per share: estimate vs actual
TNGX Revenue Trend
Quarterly revenue: estimate vs actual
TNGX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-0.31 | $-0.32 | -1.72% | $0 | -100.00% |
| Q4 25 BEAT FY | $-0.33 | $-0.29 | +11.83% | $0 | -100.00% |
| FY Full Year | $-0.90 | $-0.87 | +3.10% | $62.4M | -0.81% |
| Q3 25 BEAT | $-0.07 | $0.13 | +287.32% | $53.8M | +30.47% |
| Q2 25 MISS | $-0.34 | $-0.35 | -1.92% | $3.2M | -52.55% |
| Q1 25 MISS | $-0.35 | $-0.36 | -4.08% | $5.4M | -19.84% |